Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931849 | 0.73 | ALDH1A1 (0.39) | CNR2PARP1ALDH1A1L3MBTL1HPGD | |
| SCHEMBL37834 | 0.73 | CNR2 (0.40) | CNR2PARP1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL8235167 | 0.73 | TDO2 (0.40) | PARP1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL42808 | 0.73 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1HPGDCYP1A2CYP3A4 | |
| SCHEMBL8790012 | 0.72 | CRBN (0.57) | CNR2PARP1MEN1TSHRKMT2A | |
| SCHEMBL31334611 | 0.72 | CRBN (0.57) | CNR2PARP1MEN1TSHRKMT2A | |
| SCHEMBL4775116 | 0.72 | LMNA (0.36) | PIM1 | |
| SCHEMBL2040290 | 0.72 | MAP4K1 (0.36) | IDH1PIM1 | |
| SCHEMBL14910345 | 0.71 | CNR2 (0.53) | CNR2PARP1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL16742827 | 0.71 | CNR2 (0.44) | CNR2PARP1ALDH1A1L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | claimed |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-07-15 | — | — | US | claimed |
| WO-2011151436-A2 | NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | claimed |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| CN-107660205-B | Heterocyclic compounds as LSD1 inhibitors | 因赛特公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3626720-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3277689-B1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2016161282-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2011151436-A2 | NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| CN-101258154-B | Pyrazolo [3 as histamine H3 antagonists | GLAXO GROUP LTD | 2011-01-19 | — | — | CN | disclosed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | disclosed |
| CN-101258154-A | Pyrazolo [3, 4-D ] azepine * derivatives as histamine H3 antagonists | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | CN | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| EP-1899350-A1 | PYRAZOLO Ý3 , 4-D¨AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007025596-A1 | PYRAZOLO [3 , 4-D] AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | CNR2 2278/4885PARP1 184/4885ALDH1A1 192/4885 |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | CNR2 2426/4885PARP1 1722/4885ALDH1A1 593/4885 |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | CNR2 2278/4885PARP1 184/4885ALDH1A1 192/4885 |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR2, FGFR1 | CNR2 2426/4885PARP1 1722/4885ALDH1A1 593/4885 |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | CNR2 133/4885PARP1 2503/4885ALDH1A1 1565/4885 |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | CNR2 2278/4885PARP1 184/4885ALDH1A1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.